transthyretin amyloidosis
Dec 03, 2024
FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.
Lin BioScience Receives FDA Fast Track Designation for LBS-007 Lin BioScience, a clinical-stage biopharmaceutical company focused on developing innovative therapies for acute leukemia, announced that its lead pipeline candidate, LBS-007, has been granted Fast Track Designation by the FDA for the treatment of acu...
Read More...
Sep 03, 2024
Bayer Phase III NSCLC Trial; D&D Pharmatech Gets FDA Nod for GLP-1R Agonist in Multiple Scletosis; Merck Halts Two KEYTRUDA Trials; Novartis Expands LEQVIO After Phase III Success; Alnylam Reports Strong Phase III Data for Vutrisiran
Bayer Starts Phase III Trial In Non-Small Cell Lung Cancer (NSCLC) Bayer has officially enrolled the first patient in the global Phase III SOHO-02 trial, which will evaluate the efficacy and safety of BAY 2927088 as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutat...
Read More...
Oct 09, 2018
Notizia
FDA approves transthyretin amyloidosis therapy of Akcea, Ionis Patients with an orphan, hereditary disease that is transthyretin amyloidosis with a second new treatment option are available after the Food and Drug Administration approved Akcea Therapeutics and Ionis Pharmaceuticals' Tegsedi. As Tegsedi is approved,...
Read More...
Aug 29, 2018
Notizia
Novartis sends out orphan disease drug to LifeMax Labs LifeMax Laboratories, biotech based in San Francisco is given an authorization of a treatment by Novartis for Netherton syndrome, an orphan genetic disorder. Focus of treatment is on managing symptoms and avoiding skin infections and other complications. Life...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
